Evaluation of RECK mRNA and RECK protein in tissue and serum of breast cancer patientsAzza Hassan AbouGhalia, Eman Khairy, Manar Fouada, Hussein Abd Aleem Boshnak ; Abou Ghalia, Azza
AbstractBackground: Breast cancer (BC) is the most notorious females' cancer with high morbidity and mortality. RECK is an inhibitor of matrix metalloproteinase, and cellular invasion. Although high expression levels of RECK has been correlated with a better clinical outcome for several tumor types, its clinical significance for BC, remains unclear. The present study aimed to investigate the expression of RECK gene in BC patients to evaluate its clinical utility. Methods: The current study included 120 breast tissue and serum specimens from patients with BC, and control females. The two groups were matched for age, menopausal status, and the use of hormonal therapy or oral contraceptive pills (OCP). The expression of RECK mRNA, and protein was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and enzyme linked immunosorbent assay (ELISA), respectively. Results: The expression of both RECK mRNA and protein was lower in tissues, and sera samples obtained from BC patients than the control group. The tissue levels of RECK mRNA and RECK protein were high in premenopausal and OCP users. The sensitivity of RECK mRNA in tissue and serum was 100%. Both mRNA and protein levels of RECK in serum were positively correlated with their levels in breast tissue. Conclusion: These findings illustrate the clinical value of RECK as a molecular marker for BC, and the feasibility of liquid biopsies to determine RECK expression.
|Keywords||Breast cancer, RECK, qRT-PCR, ELISA, Circulating Biomarker||Issue Date||2018||Journal||Gene Reports||URI||http://research.asu.edu.eg/handle/123456789/1685|
Recommend this item
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.